Drugs / 5-methoxy-2-aminoindane
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05913752 | Apr 2025 → Dec 2026 expected | alcohol-related disorders | Clearmind Medicine Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2026-08-13 | Clearmind Medicine Inc. | Results Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint clearmindmedicine.com ↗
The DSMB's approval follows the successful completion of Part A of the study, where CMND-100 achieved its primary safety endpoint, demonstrating a favorable safety and tolerability profile across all planned dose levels in healthy participates. |
| 2026-08-11 | Clearmind Medicine Inc. | Results Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery clearmindmedicine.com ↗
today announced positive permeation study results from its ongoing intranasal MEAI development program. |
| 2026-08-06 | Clearmind Medicine Inc. | Results Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study clearmindmedicine.com ↗
The DSMB’s approval follows the successful completion of Part A of the study, where CMND-100 achieved its primary safety endpoint, demonstrating a favorable safety and tolerability profile across all planned dose levels in healthy participates. |
| 2026-07-30 | Clearmind Medicine Inc. | Results Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial clearmindmedicine.com ↗
CMND-100 demonstrated a consistent safety profile throughout the dose-escalation phase, including at the highest dose evaluated in the fourth cohort. |
| 2024-08-06 | Clearmind Medicine Inc. | Results Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug clearmindmedicine.com ↗
MEAI significantly reduced diet-induced obesity in mice by decreasing fat mass while preserving lean mass. |
| 2024-07-31 | Clearmind Medicine Inc. | Results Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research clearmindmedicine.com ↗
Their presentation delved into the promising results of MEAI in attenuating obesity and its related metabolic complications, showcasing its potential as a therapeutic agent in obesity management. |
| 2024-07-16 | Clearmind Medicine Inc. | Regulatory Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism clearmindmedicine.com ↗
While the Phase I/IIa clinical trial was already approved in Israel, clearance from the FDA will allow the trial to be initiated in the US. |
| 2024-03-13 | Clearmind Medicine Inc. | Regulatory Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial clearmindmedicine.com ↗ |
| 2024-02-23 | Clearmind Medicine Inc. | Regulatory Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder clearmindmedicine.com ↗ |
| 2023-03-16 | Clearmind Medicine Inc. | Regulatory Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder clearmindmedicine.com ↗ |
| 2022-06-07 | Clearmind Medicine Inc. | Results Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment clearmindmedicine.com ↗
Rats treated with MEAI spent less time in the compartment associated with cocaine. |
| 2022-06-01 | Clearmind Medicine Inc. | Regulatory Clearmind Medicine Granted Patent Approval for Psychedelic-Based Alcohol Substitute in India clearmindmedicine.com ↗ |
All press releases naming this drug 12 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-methoxy-2-aminoindane | “The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients...” NCT05913752 ↗ |
| Modality | Small molecule | “MEAI is a psychoactive compound of the aminoindane class” NCT05913752 ↗ |